Cargando…

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials

BACKGROUND: Symptoms of advanced hepatocellular carcinoma (HCC) represent a substantial burden for the patient and are important endpoints to assess when evaluating treatment. Patient-reported outcomes were evaluated in subjects with advanced HCC and baseline alpha-fetoprotein (AFP) ≥400 ng/mL treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Andrew X, Nipp, Ryan D, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Blanc, Jean-Frederic, Okusaka, Takuji, Chau, Ian, Cella, David, Girvan, Allicia, Gable, Jonathon, Bowman, Lee, Wang, Chunxiao, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437873/ https://www.ncbi.nlm.nih.gov/pubmed/32817068 http://dx.doi.org/10.1136/esmoopen-2020-000797

Ejemplares similares

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study
por: Parikh, Neehar D., et al.
Publicado: (2023)

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
por: Shao, Guoliang, et al.
Publicado: (2022)

The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases
por: Doi, Yasuhiro, et al.
Publicado: (2018)

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
por: Trojan, Jörg, et al.
Publicado: (2021)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
por: Montal, Robert, et al.
Publicado: (2019)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
por: Gao, Ling, et al.
Publicado: (2021)

Characterizations of Anti-Alpha-Fetoprotein-Conjugated Magnetic Nanoparticles Associated with Alpha-Fetoprotein for Biomedical Applications
por: Liao, Shu-Hsien, et al.
Publicado: (2017)

Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection
por: Lin, Kongying, et al.
Publicado: (2021)

Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy
por: Sun, Li-Yue, et al.
Publicado: (2022)

Human Alpha Fetoprotein in Body Fluids
por: Smith, J. A., et al.
Publicado: (1971)

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
por: Wang, Xiaoping, et al.
Publicado: (2018)

Racial disparities in alpha‐fetoprotein testing and alpha‐fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients
por: Wu, Guoyi, et al.
Publicado: (2019)

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma
por: Wei, Zhewen, et al.
Publicado: (2022)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. II. Alpha-fetoprotein-induced suppression of cytotoxic T lymphocyte development
Publicado: (1978)

Dynamic Change in Serum Alpha-fetoprotein Level Predicts Treatment Response and Prognosis of Alpha-fetoprotein-producing Gastric Cancer
por: Wang, Ruhan, et al.
Publicado: (2020)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Genetic control of alpha-fetoprotein synthesis in the mouse
Publicado: (1977)

Hepatoid adenocarcinoma of the gallbladder with production of alpha-fetoprotein
por: Lee, Jae Hoon, et al.
Publicado: (2011)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
por: Huang, Kai-Wen, et al.
Publicado: (2012)

Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma
por: Zhang, Zhiguo, et al.
Publicado: (2015)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Structures of disease-specific serum alpha-fetoprotein isoforms
por: Johnson, P J, et al.
Publicado: (2000)

Clinicopathological Characteristics of Alpha-Fetoprotein-Producing Gastric Cancer
por: Chun, Huan, et al.
Publicado: (2011)

Hepatoid carcinoma of the ovary without staining for alpha-fetoprotein
por: Sung, Ji-Hee, et al.
Publicado: (2013)

Protein profiling of alpha-fetoprotein producing gastric adenocarcinoma
por: He, Liang, et al.
Publicado: (2016)

Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?
por: Lee, Chao-Wei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4k5v16lj41t0ol3m9haoa2d329